Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83022242 | 8302224 | 2 | F | 20110822 | 20120127 | 20111122 | 20120426 | PER | PHEH2011US02492 | NOVARTIS | 34.00 | YR | M | N | 0.00000 | 20120306 | CN | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83022242 | 8302224 | 1 | PS | GILENYA | 1 | ORAL | 0.5 MG, QD, ORAL | S0010AB | 20130228 | 22527 | 0.5 | MG | |||||||
| 83022242 | 8302224 | 2 | SS | FAMPRIDINE | 1 | 0 | 10 | MG | BID | ||||||||||
| 83022242 | 8302224 | 4 | C | AMINO ACIDS (NO INGREDIENTS/SUBSTANCES) | 2 | 0 | |||||||||||||
| 83022242 | 8302224 | 6 | C | VITAMINS NOS (VITAMINS NOS) | 2 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 83022242 | 8302224 | 1 | Relapsing-remitting multiple sclerosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 83022242 | 8302224 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 83022242 | 8302224 | FATIGUE |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 83022242 | 8302224 | CSM |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 83022242 | 8302224 | 1 | 20110822 | 0 |